Association between PD-1/PD-L1 Expression and Clinicopathological Parameters as well as Prognosis in Neuroendocrine Neoplasms of the Digestive System: A Systematic Review and Meta-Analysis.

Authors

Qiming Zheng, Xinyue Xie, Qingjun Guo, Chiyi Chen, Wentao Jiang

Published in

Endocrine-related cancer. Aug 24, 2026. Epub Aug 24, 2026.

Abstract

Neuroendocrine neoplasms (NENs) are a highly heterogeneous group of tumors originating from the neuroendocrine system, predominantly occurring in the gastrointestinal tract and lungs. This meta-analysis aimed to clarify the association of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) expression with clinicopathological parameters and prognosis in patients with digestive system NENs. A systematic literature search was performed in PubMed, Web of Science, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, and China BioMedical Literature Database (CBM) from each database's inception to February 2026. Eligible studies were analyzed using Stata 17.0 software, with 29 studies involving 2,633 patients included.Results showed no significant association between PD-1 expression and clinicopathological parameters or prognosis. In contrast, PD-L1 expression was closely correlated with high tumor grade (OR=2.73, 95%CI: 1.33-5.60; p=0.006) and pancreatic primary tumor site (OR=2.58, 95%CI: 1.21-5.52; p=0.014). Regarding prognosis, positive PD-L1 expression was associated with inferior overall survival (OS) in gastroenteropancreatic NENs (GEP-NENs) (HR=1.77, 95%CI: 1.25-2.51; p=0.001) but favorable OS in esophageal NENs (HR=0.60, 95%CI: 0.37-0.99; p=0.047). In conclusion, PD-L1 expression correlates with high tumor grade and pancreatic origin. It serves as a predictive biomarker for poor OS in GEP-NENs but favorable prognosis in esophageal NENs, highlighting the divergent prognostic value of the PD-1/PD-L1 axis across digestive system NEN subtypes. These findings provide hypothesis-generating evidence for the potential rationale of immune checkpoint inhibitors in high-grade or poorly differentiated GEP-NENs, although their clinical application requires further prospective validation.

PMID:
42636443
Bibliographic data and abstract were imported from PubMed on 25 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.